Menu Search
Equities

Fuji Pharma Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
FUP:FRA

Fuji Pharma Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)11.60
  • Today's Change-0.40 / -3.33%
  • Shares traded150.00
  • 1 Year change+28.18%
  • Beta0.6535
Data delayed at least 15 minutes, as of Feb 06 2026 07:04 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Fuji Pharma Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of medical products. The Company is engaged in the manufacture and sale of hormone medicines for obstetrics and gynecology department, as well as injectable drugs for radiological department such as radiopaque dye for urinary tracts and blood vessels through its branches. The Company's products are primarily used to treat dysmenorrhea, endometriosis, pregnancy and childbirth, and menopause.

  • Revenue in JPY (TTM)54.57bn
  • Net income in JPY2.33bn
  • Incorporated1965
  • Employees1.76k
  • Location
    Fuji Pharma Co Ltd6FIzumidate Bujin Tori, 5-7, Sanban-choCHIYODA-KU 102-0075JapanJPN
  • Phone+81 335563344
  • Fax+81 335564455
  • Websitehttps://www.fujipharma.jp/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.